Peptide Advocacy · 5 Compounds
Cellular
Repair
Peptides are amino acid chains — the body's own signaling molecules. They represent the frontier of regenerative medicine that the pharmaceutical industry is racing to patent and restrict.
Cellular Repair Visualization
BPC-157
Body Protection Compound-157
A pentadecapeptide derived from human gastric juice. BPC-157 accelerates healing of tendons, ligaments, muscle, bone, and the GI tract. It promotes angiogenesis, modulates nitric oxide synthesis, and has demonstrated remarkable tissue-repair properties across hundreds of animal studies.
Targets
Status
Extensive preclinical data. No FDA-approved human trials yet. Widely used in integrative medicine.
KPV
Lysine-Proline-Valine
A tripeptide derived from alpha-MSH (alpha-melanocyte-stimulating hormone). KPV is a potent anti-inflammatory that works by inhibiting NF-κB activation and reducing pro-inflammatory cytokine production. Particularly effective for gut inflammation and IBD.
Targets
Status
Published research on anti-inflammatory mechanisms. Used clinically for gut-specific inflammation.
Thymosin Alpha-1
Thymosin Alpha-1 (Tα1)
A thymic peptide that modulates the immune system by enhancing T-cell function, NK cell activity, and dendritic cell maturation. Approved in over 35 countries for hepatitis B and C treatment. Critical for immune reconstitution in chronic infections like Lyme disease.
Targets
Status
FDA Orphan Drug designation. Approved in 35+ countries. Marketed as Zadaxin internationally.
LL-37
Cathelicidin LL-37
A human antimicrobial peptide produced by the innate immune system. LL-37 directly kills bacteria, fungi, and viruses by disrupting their cell membranes. It also modulates the immune response and promotes wound healing. Particularly relevant for biofilm-forming infections.
Targets
Status
Endogenous human peptide. Research ongoing for therapeutic applications in chronic infections.
Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
A modified angiotensin IV analog that is 10 million times more potent than BDNF at promoting new synapse formation. Developed at Washington State University for cognitive enhancement and potential Alzheimer's treatment. Crosses the blood-brain barrier.
Targets
Status
Preclinical research at WSU. Patent held for Alzheimer's treatment. Not yet in human clinical trials.
Advocacy Position
The Peter Franco Foundation advocates for continued research access to therapeutic peptides. We oppose regulatory efforts to restrict access to compounds like BPC-157 and Thymosin Alpha-1 that have demonstrated remarkable safety profiles and therapeutic potential across thousands of studies. Healing should not be gatekept by patent holders.
Explore Treatment ModalitiesMedical Disclaimer
The information provided here is for educational purposes only and does not constitute medical advice. Peptide therapy should be administered under the supervision of a qualified healthcare provider. The PFF Foundation advocates for access but does not prescribe or sell peptides.